Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis

Abstract

Renal cell carcinoma (RCC) is the predominant form of kidney cancer. It is a highly prevalent form of solid tumor, and the limited availability of accurate disease models has impeded progress in the field of human kidney cancer research and treatment. Recent pharmaceutical advances, such as immune checkpoint inhibitors and targeted treatments, have shown promising results for metastatic RCC. Collaborative clinical trials will play a vital role in effectively incorporating these regimens into clinical practice. This systematic review and meta-analysis aim to assessing the efficacy and safety of nivolumab-ipilimumab, pembrolizumab-axitinib and pazopanib in treatment of renal cell carcinoma. The clinical outcome indicators that will be evaluated include overall survival, progression-free survival, hazard ratio, overall adverse events, and severe adverse events. The objective of this research is to identify therapeutic interventions that have the potential to improve the long-term management of renal cell carcinoma (RCC) on a worldwide scale.